Back

Effect of abelacimab vs. rivaroxaban on total bleeding events in patients with atrial fibrillation: an analysis from AZALEA–TIMI 71

29 August 2026 (10:00 - 10:10)
Organised by: Logo
Congress Presentation Part of: Optimising antithrombotic therapy in atrial fibrillation Oral Anticoagulation ESC Professional Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Siddharth Patel

Brigham and Women's Hospital, Boston (United States of America)

4 More presentations in this session

Presentation thumbnail
Reduced-dose direct oral anticoagulation vs antiplatelet strategies after left atrial appendage occlusion in atrial fibrillation. a triple target trial emulation from a federated research network
Professor L. Fauchier (Tours, FR)
Abstract Slides Video
Presentation thumbnail
Direct oral anticoagulants in very elderly (≥90 years) patients with atrial fibrillation: observed versus predicted thromboembolism and bleeding risk, and HAS-BLED performance
Doctor K. Abd El Hay (Kfar Saba, IL)
Abstract Slides Video
Presentation thumbnail
Asundexian edges out milvexian: superior stroke reduction with safer bleeding profile in factor XIa inhibition – a network meta-analysis revolutionizing secondary prevention
Doctor K. Keswani (Vadodara, IN)
Abstract Slides Video
Presentation thumbnail
Real-world complication profiles of left atrial appendage occlusion devices: a MAUDE database analysis of 8,406 adverse events
Doctor K. Abdelsayed (Minneapolis, US)
Abstract Slides Video

Access the full session

Session thumbnail
Optimising antithrombotic therapy in atrial fibrillation
Video

The Event

Event poster

ESC Congress 2026

29 August 2026 10:00 CET
You may be interested in
thumbnail
Congress Presentation
Long-acting Factor XI Inhibition and Periprocedural Bleeding: A Secondary Analysis from AZALEA-TIMI 71
2 September 2024
thumbnail
Congress Session
Evolution of anticoagulation therapy in patients with atrial fibrillation
30 August 2025
thumbnail
Congress Presentation
Atrial fibrillation
26 August 2023
thumbnail
Congress Presentation
Incidence and predictors of major bleeding among patients receiving apixaban or aspirin for subclinical atrial fibrillation: insights from the ARTESiA sub-analysis
31 March 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources